Loading
A phase 3 trial testing Bexobrutideg in chronic lymphocytic leukaemia, now recruiting.
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL is a phase 3 interventional study registered as NCT07516093, led by Nurix Therapeutics, and recruiting on the registry. Official title: A Phase 3, Randomised, Open-label, Multicenter Study of NX-5948 Versus Pirtobrutinib in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukaemia (CLL)/Small Lymphocytic Lymphoma (SLL). Planned enrolment is 620 participants (estimated). The study started in 2026-08-03 and primary completion is expected in 2029-10. No results have been posted on ClinicalTrials.gov.
Shares Bexobrutideg, Nurix Therapeutics, Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia.
Shares Bexobrutideg, Nurix Therapeutics, Chronic lymphocytic leukaemia.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia.
Shares Relapsed or refractory chronic lymphocytic leukaemia, Chronic lymphocytic leukaemia.